CAS 865663-98-5 | BITO-005 : Bitopertin
(World's Largest Pharmaceutical Supplier)

CAS 865663-98-5 is a chemical compound with the molecular formula C17H15N3O3S. It is also known by its trade name, Ribociclib. Ribociclib is a selective cyclin-dependent kinase inhibitor and is primarily used in the treatment of advanced breast cancer.

Ribociclib works by inhibiting the activity of cyclin-dependent kinases 4 and 6, which are involved in cell cycle progression. This inhibition leads to a decrease in the proliferation of cancer cells and ultimately slows down the growth of tumors.

Ribociclib was first approved by the United States Food and Drug Administration (FDA) in 2017 and has since been approved for use in several other countries. It is typically used in combination with other medications, such as letrozole or fulvestrant, for the treatment of hormone receptor-positive, HER2-negative advanced breast cancer.

In clinical studies, Ribociclib has been shown to significantly prolong progression-free survival in patients with advanced breast cancer. It has also been shown to be generally well-tolerated, with common side effects including fatigue, nausea, and neutropenia.

In addition to its use in breast cancer treatment, Ribociclib is currently being investigated for its potential use in other types of cancer, such as lung cancer and melanoma.

Overall, Ribociclib represents an important advancement in cancer treatment and has the potential to significantly improve outcomes for patients with advanced breast cancer.